

---

# Infectious Mononucleosis

---

R. S. CHANG, M.D., D.Sc.

---

# Infectious Mononucleosis

---

R. S. CHANG, M.D., D.Sc.

*Professor of Medical Microbiology  
and Family Practice  
School of Medicine  
University of California  
Davis, California*

*Medical Director  
Davis Free Clinics  
Davis, California*

*Professional Director  
Tissue Typing Laboratory  
University of California  
Davis Medical Center  
Davis, California*



G. K. Hall Medical Publishers  
Boston, Massachusetts

---

Chang, R. S.

Infectious mononucleosis

Copyright © 1980

G. K. Hall Medical Publishers

70 Lincoln Street

Boston, Massachusetts 02111

Library of Congress Catalog No. 79-22433

ISBN 0-8161-2153-2

Bibliography

Includes index.

1. Mononucleosis. 2. Epstein-Barr virus. 1. Title.

RC147.G6C46 616.1'5

All rights reserved. This book, or parts thereof, may not be reproduced in any form without written permission of the publisher.

80 81 82 83 / 4 3 2 1

The authors and publisher have worked to ensure that all information in this book concerning drug dosages, schedules, and routes of administration is accurate at the time of publication. As medical research and practice advance, however, therapeutic standards may change. For this reason, and because human and mechanical errors will sometimes occur, we recommend that our readers consult the *PDR* or a manufacturer's product information sheet prior to prescribing or administering any drug discussed in this volume.

---

# Preface

---

I am a neophyte in the study of infectious mononucleosis (IM). I did not get seriously involved until 1968, when the Henles described the first major clue to the etiologic relationship between the Epstein-Barr virus (EBV) and IM. Once involved, I became fascinated by the epidemiologic, clinical, and laboratory aspects of IM. Being a neophyte has at least one advantage—the neophyte is able to study the disease with an open mind, without preconceived notions, and with no stance that has to be defended.

I read and reread Hoagland's authoritative monograph on IM published in 1967, during the pre-EBV era. He emphasized the monotonous regularity with which a few basic signs and symptoms recurred in IM patients. Yet, other clinicians described IM as a disease with protean manifestations and with the capability of simulating diseases of many organ systems. Which notion is correct? Perhaps both are correct—the difference may be due entirely to the investigators' emphasis on either classic or more exceptional cases. Looking at Hoagland's stringent criteria for the diagnosis of IM, I am impressed by the usefulness of his criteria in an era when IM was a disease of unknown etiology, but I cannot help wondering whether his criteria may not be too restrictive in the post-EBV era. Hoagland used the term *infectious mononucleosis* rather than *glandular fever* presumably because of his belief that IM is infectious. Yet, he freely acknowledged that the epidemiologic feature of IM was inconsistent with classic infectious disease. Can we resolve this apparent contradiction in the post-EBV era?

The symposium volume on IM, edited by Carter and Penman and

published in 1969, underscored two additional facts: IM is a self-limited lymphoproliferative disease, and IM patients produce a large number of abnormal antibodies, some of which react against the host's own tissue. Can this self-limited lymphoproliferation become a progressive one under certain host and/or environmental conditions, and how does the host produce an array of antibodies totally unrelated to the EBV? Can we find satisfactory answers from current immunologic concepts?

As a physician with considerable background in public health, and with a chosen career as a medical educator who also does laboratory research, I have attempted to read as many publications as I can about IM. I must confess that I am overwhelmed by the literature. Not only is the number of publications large, but the spectrum of interest is wide. Literature search through MEDLARS yielded over 800 publications in English between July 1975 and June 1978 on the EBV and IM! These publications appeared in a range of journals from the very basic (*Journal of Molecular Biology*) to the very clinical (*Age and Ageing*). Even psychiatric journals contain articles on IM.

This new monograph on IM can serve two useful purposes. First, it provides an up-to-date summary of the latest (to 1979) information on IM, and second, it catalogs references that give in-depth information on specific aspects of IM.

Reviewing the vast amounts of information contained in the references enabled me to discern relationships. For example, certain biological attributes of the EBV appear to cause certain pathological findings which, in turn, appear to be responsible for certain clinical manifestations of IM. Through our knowledge of the biological attributes of the EBV, we can almost describe steps in the pathogenesis of IM and predict its clinical manifestations. With knowledge of the EBV and its interaction with the host, we can explain why IM is what it is. Medical educators are acutely aware of the difficulty in motivating some medical students to learn basic medical sciences because of their "irrelevance" to clinical medicine. Study of the disease IM bridges the "relevance" gap because in it the relation of the basic to the clinical sciences is readily perceived.

R. S. Chang, M.D., D.Sc.

---

# Contents

---

## Preface

<b>Chapter 1. The Epstein-Barr Virus</b>	<b>1</b>
1.1 Discovery	1
1.2 Morphology	3
1.3 Physicochemical characteristics	5
1.4 Biological characteristics	5
1.5 EBV-associated antigens	6
1.6 Antigenic relation to other herpesviruses	9
1.7 EBV strains	9
1.8 EBV-like agents from nonhuman primates	11
<b>Chapter 2. Epstein-Barr Virus-Cell Interaction</b>	<b>15</b>
2.1 Susceptible cells	15
2.2 EBV replication	17
2.2.1 Attachment	18
2.2.2 Penetration and uncoating	18
2.2.3 Expression of early genes	18
2.2.4 Viral DNA synthesis	19
2.2.5 Expression of late genes	19
2.2.6 Maturation and release	20
2.3 Cell transformation	21
2.4 Cytotoxicity	22

2.5	Characteristics of EBV-transformed lymphoid cells	22
2.5.1	In vitro growth	22
2.5.2	EBV genomes	23
2.5.3	EBV-associated antigens	23
2.5.4	Chromosomal abnormalities	24
2.5.5	Production of interferons and other lymphokines	24
2.5.6	HLA antigens	24
2.5.7	Secretion of immunoglobulins (Ig.)	24
2.5.8	Ability to support growth of other viruses	27
2.6	Transformed human lymphoid cells without EBV genomes	27
<b>Chapter 3.</b>	<b>Animal Pathogenicity</b>	<b>29</b>
3.1	Natural infections	29
3.2	Experimental infections	30
3.3	Inoculation of autologous EBV-transformed cells	31
3.4	Heterologous transplantation of EBV-transformed cells	32
3.5	Synergism between the EBV and malarial parasites	34
<b>Chapter 4.</b>	<b>Pathology</b>	<b>35</b>
4.1	Anatomical pathology	35
4.1.1	Lymph nodes	35
4.1.2	Spleen	36
4.1.3	Liver	36
4.1.4	Nervous system	37
4.1.5	Bone marrow	37
4.1.6	Kidney	39
4.1.7	Myocardium	40
4.1.8	Other organs	40
4.2	Immunopathology	40
4.2.1	Abnormal antibodies	40
4.2.2	Circulating immune complex	41
4.2.3	Abnormal T cell proliferation	45
4.2.4	Nonspecific suppression of cell-mediated immunity	47
4.3	Pathogenesis	47
4.4	The EBV and IM	49

<b>Chapter 5. Clinical Manifestations</b>	51
5.1 Hoagland's diagnostic criteria	51
5.2 Subclinical IM	52
5.3 Incubation period	52
5.4 Common signs and symptoms	53
5.5 Organ system involvement	54
5.5.1 Skin	54
5.5.2 Nervous system	55
5.5.3 Liver	56
5.5.4 Heart	56
5.5.5 Lung, pleura, and mediastinum	57
5.5.6 Pancreas	57
5.5.7 Intestine	57
5.5.8 Kidney	58
5.5.9 Genitalia	58
5.5.10 Eye	58
5.5.11 Blood	58
5.5.12 Spleen	58
5.5.13 Metabolism	58
5.5.14 Thyroid	58
 <b>Chapter 6. Hematologic Abnormalities</b>	 59
6.1 Anemia	59
6.2 Thrombocytopenia	60
6.3 Neutropenia	61
6.4 Lymphocytosis	61
 <b>Chapter 7. Complications, Sequelae, Prognosis</b>	 65
7.1 Splenic rupture	65
7.2 Acute upper airway obstruction	66
7.3 Hepatoencephalopathy	66
7.4 Acquired agammaglobulinemia	66
7.5 Disseminated intravascular coagulation	67
7.6 Pharyngeal and tonsillar hemorrhage	67
7.7 Other hemorrhagic phenomena	67



7.8 Secondary bacterial infection	68
7.9 Death	68
<b>Chapter 8. Humoral and Cellular Immunity</b>	<b>71</b>
8.1 Heterophil and Paul-Bunnell-Davidsohn (PBD) antibodies	71
8.1.1 Heterophil antibodies	71
8.1.2 The PBD antibody	71
8.1.3 Forssman antibodies	72
8.1.4 The PBD antibody in IM	72
8.1.5 The PBD antibody in healthy subjects	73
8.1.6 The PBD antibody in other diseases (false-positive PBD reaction)	73
8.1.7 Anamnestic resurgence of the PBD antibody after IM	74
8.2 EBV antibodies	74
8.2.1 Antibody against the EBV capsid antigens	74
8.2.2 EBV capsid IgM	76
8.2.3 Antibody against the EBV-associated nuclear antigen	76
8.2.4 Antibody against the EBV early antigens	77
8.2.5 Neutralizing antibodies	77
8.2.6 Antibodies against EBV-specific membrane antigens	78
8.3 EBV-specific cellular immunity	78
8.3.1 Specific blastoid activation	78
8.3.2 Specific release of the leukocyte migration inhibitory factor (LIF)	79
8.3.3 Specific release of the leukocyte adherence inhibitory factor (LAI)	80
8.3.4 Macrophage migration inhibitory factor (MIF)	80
8.3.5 Immune interferon	80
8.3.6 Monocyte migration	80
8.3.7 Intradermal delayed-hypersensitivity to crude EBV antigens	81

8.4 Killing of EBV-transformed cells	81
8.5 Quenching of EBV infection	84
<b>Chapter 9. Diagnosis</b>	87
9.1 Clinical criteria	87
9.2 Hematologic criteria	87
9.3 Heterophil serology	88
9.4 EBV serology	89
9.5 EBV virology	90
9.6 EBV-transformed cells in the blood	91
9.7 Application of diagnostic criteria	93
<b>Chapter 10. Latent and Persistent Active Epstein-Barr Virus Infections, Chronic Infectious Mononucleosis and Recurrent Infectious Mononucleosis</b>	101
10.1 Latent EBV infection	101
10.2 Persistent active EBV infection	102
10.3 Chronic IM	102
10.4 Recurrent IM	103
<b>Chapter 11. Epstein-Barr Virus Infections in Special Hosts</b>	105
11.1 Fetuses	105
11.2 Infants	106
11.3 Aged persons	106
11.4 Persons receiving immunosuppressants	107
11.5 Immunodeficient persons	107
<b>Chapter 12. Prognosis, Treatment, and Immunization</b>	113
12.1 Prognosis	113
12.2 Treatment	114
12.2.1 General	114
12.2.2 Corticosteroids	114
12.2.3 Antibiotics	115
12.2.4 Chloroquine	116
12.2.5 Methisazone	116
12.2.6 Deoxyribonuclease	116
12.3 Immunization	116

<b>Chapter 13. Epidemiology</b>	119
13.1 Epidemiology of IM among general populations	119
13.1.1 Annual incidence rates	119
13.1.2 Age-specific incidence rates	120
13.1.3 Incidence rates by sex and age	120
13.1.4 Incidence rates by race	120
13.1.6 Incidence rates by season	121
13.1.7 Long-term trends	121
13.1.8 Rural and urban distribution	121
13.1.9 Contagiousness	121
13.2 Epidemiology of IM among specific populations	121
13.2.1 College students	121
13.2.2 Boarding school students	123
13.2.3 United States armed forces	123
13.3 Prevalence of EBV infections in different communities	123
13.4 Prevalence of herpesvirus antibodies in institutionalized and noninstitutionalized subjects	126
13.5 Acquisition of EBV infections	127
13.5.1 Infants in Ghana	127
13.5.2 Infants and children in Montreal and Cleveland	128
13.5.3 College students	128
13.5.4 Household contacts	129
13.5.5 Crew members in a Polaris submarine	129
13.5.6 A military population	129
13.5.7 Sexual partners	130
13.6 Epidemics	130
13.7 Prevalence of EBV excretors	130
13.8 Histocompatibility (HLA) antigens	131
13.9 Summary and hypothesis	131
<b>Chapter 14. The Epstein-Barr Virus and Nonneoplastic Diseases Other Than Infectious Mononucleosis</b>	135
14.1 Postperfusion syndrome (posttransfusion mononucleosis)	135

14.2	Posttransfusion hepatitis	135
14.3	Recurrent exudative tonsillitis	136
14.4	Guillain Barré syndrome and Bell's palsy	136
14.5	Subacute sclerosing panencephalitis	137
14.6	Kawasaki disease (mucocutaneous lymph node syndrome)	137
14.7	Cat-scratch disease	137
14.8	Sarcoidosis	138
14.9	Lepromatous and tuberculoid leprosy	138
14.10	Multiple sclerosis	138
14.11	Systemic lupus erythematosus	139
14.12	Rheumatoid arthritis	139
14.13	Chromosomal damage	140
14.14	Infectious lymphocytosis	140
<b>Chapter 15.</b>	<b>The Epstein-Barr Virus and Neoplastic Diseases</b>	<b>143</b>
15.1	Acute lymphoblastic leukemia	143
15.2	Hodgkin's disease	144
15.3	Burkitt's lymphoma	145
15.4	Nasopharyngeal carcinoma	146
15.5	Cancer risks	147
<b>Appendix:</b>	<b>A Glossary of Cell Lines Commonly Used in EBV Studies</b>	<b>149</b>
<b>References</b>		<b>151</b>
<b>Index</b>		<b>203</b>

## Chapter 1.

---

# The Epstein-Barr Virus

---

### 1.1 Discovery

Based on his extensive epidemiologic observations, Burkitt proposed the provocative hypothesis that a lymphoma syndrome among children in tropical Africa might be caused by an arthropod-borne virus (1963). This hypothesis generated a colossal volume of research on this tumor, now known as *Burkitt's lymphoma*. One type of research was the examination of Burkitt's lymphoma tumor tissue for viruses. Several viruses were found (Simons and Ross 1965; Bell et al. 1966; Woodall et al. 1965); one of them is a herpesviruslike particle, now known as the *Epstein-Barr virus* (EBV).

Pulvertaft (1964) and Epstein and Barr (1964) successfully propagated lymphoid cells from biopsies of Burkitt's lymphoma. Examining thin sections of these lymphoid cells with the electron microscope, Epstein, Achong, and Barr (1964) and Epstein and associates (1965) found herpesviruslike particles which were biologically and antigenically distinct from any of the human herpesviruses known at that time. Soon after, continually multiplying lymphoid cells were successfully isolated from other Burkitt's lymphomas (Steward et al. 1965; Rabson et al. 1965), from the blood and lymph nodes of patients with leukemia or solid cancers (Iwakata and Grace 1964; Zeve, Lucas, and Manaker 1966; Jensen et al. 1967), from the blood and bone marrow of infectious mononucleosis (IM) patients (Gerber and Birch 1967b; Pope 1967; Diehl et al. 1968; Moses et al. 1968; Benyesh-Melnick et al. 1968) and from the blood of healthy persons (Moore, Gerner, and Franklin 1967; Gerber and Monroe 1968). Herpesviruslike particles were also found in

the cell lines in some of the continually multiplying lymphoid cells. To determine the antigenic relatedness of these herpesviruslike particles, Epstein and Achong immunized rabbits with virus particles from a line of Burkitt's lymphoma cells and tested the antiserum on viruses derived from five other sources (1968*a*; *b*). The viruses were all related antigenically. It was proposed that this group of antigenically related herpesviruslike particles, found in human lymphoid cells derived from diverse sources, be named the Epstein-Barr virus.

Taking advantage of the facts that the EBV can transform human lymphocytes, that the EBV is implicated as the etiologic agent of IM, and that IM is sometimes referred to as the "kissing disease," Chang and Golden tested the oropharyngeal secretions of IM patients for leukocyte-transforming activity. They reported in 1971 that the throat washings of IM patients contained a filterable agent capable of transforming human peripheral leukocytes into rapidly and persistently multiplying lymphoid cells. Further studies (Gerber et al. 1972; Chang et al. 1973; Golden et al. 1973; Chang, Lewis, and Abildgaard 1973; Strauch et al. 1974; Sumaya 1975) showed that many persons not suffering from IM were also excretors of this leukocyte-transforming agent. The key question is whether the transforming agent is the EBV. Because it is difficult to propagate the transforming agent in human leukocyte culture or any tissue-culture system, sufficient quantities of it cannot be obtained for direct-identification studies (Chang, Lewis, and Abildgaard 1973).

Given the difficulty of propagating the leukocyte-transforming agent, its identification has to be approached by indirect means through the study of leukocytes transformed by it. Pereira and associates found an occasional herpesviruslike particle in a transformed cell (1972). Gerber and associates (1972) and Pagano (1975) found in the transformed cell a deoxyribonucleic acid (DNA) sequence homologous to the DNA of a strain of EBV. Strauch and associates found EBV antigens in the transformed cell (1974). Miller, Niederman, and Andrew neutralized the leukocyte-transforming activity of the transforming agent with two human sera that contained EBV antibody but not with two human sera that did not contain EBV antibody (1973). Lipman and associates described seeing a herpesvirus in a throat washing with transforming activity (1975). Considering all the indirect evidence, we can say that the transforming agent is probably the EBV.


What must be done to prove conclusively that the oropharyngeal transforming agent is the EBV? We must show that the transforming

potency of throat washings varies proportionately with the number of herpesviruslike particles present. We must also show the immunologic relatedness of the transforming agent and the prototype EBV by reciprocal neutralization tests using monospecific antisera obtained from specifically immunized animals rather than from selected humans. There are two reasons why these simple experiments have not yet been done. First, it is difficult to obtain a sufficient quantity of the transforming agent for experimentation because the transforming agent propagates poorly in vitro. Second, it is difficult to get monospecific sera because rabbits immunized with the EBV apparently fail to form a specific neutralizing antibody (Hampar and associates 1970; Vestergaard and associates 1978). Until conclusive evidence is obtained, it is proposed that the transforming agent in throat washings be referred to as the *oropharyngeal EBV* to distinguish it from the EBV found in continuously propagated lymphoid cells. Since there is no assurance that the EBV derived from one lymphoid cell line is necessarily identical to the EBV derived from another lymphoid cell line, it is also useful to indicate the source of the virus. For example, *P3HR-1 EBV* refers to the EBV released by the P3HR-1 cell line.

Recently, Coope and associates (1979) and Thorley-Lawson (1979) were successful in raising EBV-neutralizing antibodies in rabbits with materials derived from EBV-producer lymphoid cell lines. If their findings can be extended to the oropharyngeal EBV, it should be possible to delineate the exact antigenic relationship between the oropharyngeal and "prototype" EBV by reciprocal neutralization tests with monospecific antisera.

## 1.2 Morphology

Epstein and associates (1965) described the EBV found in Epstein-Barr (EB) Burkitt's lymphoma cell lines as a virus similar to the herpes simplex virus in appearance except for its smaller size (figs. 1.1–1.3). Cross sections of the virion reveal a central dense core surrounded by two membranes. The diameters of the central core (nucleoid), inner membrane (nucleocapsid) and outer membrane (mature virion) are 45–50, about 75, and 110–115 nm, respectively. Nucleocapsids are found primarily in the nucleus or cytoplasm of degenerating rather than healthy cells. Mature virions are always surrounded by a fine membrane within the cytoplasm. Toplin and Schidlovsky studied partially purified virus from



**Figs. 1.1–1.3.** Electron micrographs of thin-sectioned Epstein-Barr virus-transformed cells derived from Burkitt's lymphoma. In figure 1.1 numerous capsids and nucleocapsids are visible in the nucleus. In figure 1.2 a mature virion (long arrow) is seen within a membrane-bounded cytoplasmic space (m = mitochondria; s = spindle tubule; x = a space into which a virus particle appears to be maturing by budding). Figure 1.3 shows a detail of a mature virion. Magnifications: figure 1.1 76,500x; figure 1.2 42,000x; figure 1.3 213,500x (Epstein et al. 1965).



the EB-3 cell, confirmed Epstein and associates' finding, and further showed that the mature virion was enveloped and contained a nucleocapsid with icosahedral symmetry (1966). The number of capsomers per nucleocapsid is estimated at 162. The EBV released by the B95-8 marmoset cell line (Miller et al. 1974) and the oropharyngeal EBV (Lipman et al. 1975) are morphologically similar to the EBV found in EB-3 cells (Epstein et al. 1965). Miller and associates subsequently found the median diameter of the EBV nucleocapsid to be 110 nm rather than 75 nm (1974).

### 1.3 Physicochemical characteristics

EBV released by the EB-3 cell has a density of 1.19–1.21 g/cm<sup>3</sup> (Toplin and Schidlovsky 1966). The genome of virions released by the P3HR-1 lymphoma cell (Hinuma et al. 1967a) and the B95-8 marmoset cell (Miller and Lipman 1973) is a linear molecule of double-stranded DNA with a density of 1.718–1.720 g/cm<sup>3</sup>, a molecular weight of about 10<sup>8</sup> daltons, and a guanine-cytosine content of 57–59% (Schulte-Holthausen and zur Hausen 1970; Pritchett, Hayward, and Kieff 1975; Sugden, Summers, and Klein 1976; Adams et al. 1977). Results of a nucleic-acid hybridization study showed that the P3HR-1 virus had over 97% of the DNA sequences of the B95-8 virus, but the B95-8 virus lacked about 15% of the sequences of the P3HR-1 virus (Pritchett, Hayward, and Kieff 1975). Another study showed that the P3HR-1 and B95-8 EBV shared about 90% of their nucleotide sequences (Sugden, Summers, and Klein 1976). The DNA from these two EBVs are clearly not identical.

Preliminary analysis of proteins from the P3HR-1 and B95-8 virions revealed at least 33 molecular species of polypeptides with molecular weights from 28,000–290,000 daltons (Dolyniuk, Pritchett, and Kieff 1976). Being an enveloped virion, the infectivity of the EBV is destroyed by ether (Pope, Horne, and Scott 1969).

### 1.4 Biological characteristics

The four important biological characteristics of the EBV are its ability to: (1) transform human lymphoid cells, (2) induce lymphoma in marmosets, (3) cause IM in humans, and (4) persist in an infected host. These characteristics are discussed in chapters 2, 3, 4, and 10.